Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
W.Y. Craig, L.M. Neveux, G.E. Palomaki, M.M. Cleveland, J.E. Haddow.
Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies.
Clin Chem, 44 (1998), pp. 2301-2306
[2.]
J. Danesh, R. Collins, R. Peto.
Lipoprotein(a) and coronary heart disease. meta-analysis of prospective studies.
Circulation, 102 (2000), pp. 1082-1085
[3.]
G. Utermann.
Lipoprotein(a).
The metabolic and molecular bases of inherited disease, pp. p.2753-p.2787
[4.]
K.M. Kostner, G.M. Kostner.
Lipoprotein(a): still an enigma?.
Curr Opin Lipidol, 13 (2002), pp. 391-396
[5.]
A.A. Ariyo, C. Thach, R. Tracy.
for the cardiovascular health study investigators. lp(a) lipoprotein, vascular disease, and mortality in the elderly.
N Engl J Med, 349 (2003), pp. 2108-2115
[6.]
M.L. Koschinsky, S.M. Marcovina.
Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity.
Curr Opin Lipidol, 15 (2004), pp. 167-174
[7.]
A. Eckardstein Von, H. Schulte, P. Cullen, G. Assmann.
Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk.
J Am Coll Cardiol, 37 (2001), pp. 434-439
[8.]
M.P. Schlaich, S. John, M.R. Langenfeld, K.J. Lackner, G. Schmitz, R.E. Schmieder.
Does lipoprotein(a) impair endothelial function?.
J Am Coll Cardiol, 31 (1998), pp. 359-365
[9.]
G. Dangas, R. Mehran, P.C. Harpel, S.K. Sharma, S.M. Marcovina, G. Dube, et al.
Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation.
J Am Coll Cardiol, 32 (1998), pp. 2035-2042
[10.]
S.M. Marcovina, M.L. Koschinsky.
Evaluation of lipoprotein(a) as a thrombotic factor: progress bench to bedside.
Curr Opin Lipidol, 14 (2003), pp. 361-366
[11.]
L. Berglund.
Lipoprotein(a): where does the atherogenicity reside?.
J Lab Clin Med, 139 (2002), pp. 131-132
[12.]
A.M. Scanu.
Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications.
Curr Atheroscler Rep, 5 (2003), pp. 106-113
[13.]
J.J. Gómez-Barrado, S. Turégano, J.C. García-Rubira, J.M. Cruz.
El fenotipo de lipoproteína(a): ¿un marcador genético de enfermedad coronaria?.
Clin Invest Arterioscler, 16 (2004), pp. 127-132
[14.]
S. Martín, J. Pedro-Botet, J. Joven, J.M. Simó, M.G. Ladona, M. Paversi, et al.
Heterozygous apolipoprotein(a) status and protein expression as a risk factor for premature coronary heart disease.
J Lab Clin Med, 139 (2002), pp. 181-187
[15.]
A.M. Scanu.
Lp(a) lipoprotein-coping with heterogeneity.
N Engl J Med, 349 (2003), pp. 2089-2090
[16.]
National cholesterol education program (NCEP). expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report.
Circulation, 106 (2002), pp. 3143-3421
[17.]
R.M. Conroy, K. Pyörälä, A.P. Fitzgerald, S. Sans, A. Menotti, G. De Backer, et al.
Estimation of ten-year risk of fatal cardiovascular disease in europe: the SCORE project.
Eur Heart J, 24 (2003), pp. 987-1003
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.